DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,739,074 | -41.4% | 423,610 | -16.2% | 0.03% | -41.3% |
| Q2 2023 | $14,908,865 | +275.1% | 505,214 | +253.5% | 0.05% | +228.6% |
| Q4 2022 | $3,974,855 | +276.1% | 142,929 | +315.2% | 0.01% | +180.0% |
| Q3 2022 | $1,057,000 | +146.4% | 34,421 | +530.0% | 0.01% | +150.0% |
| Q2 2021 | $429,000 | -87.2% | 5,464 | -90.7% | 0.00% | -86.7% |
| Q1 2021 | $3,342,000 | -60.0% | 58,525 | -41.3% | 0.02% | -59.5% |
| Q4 2020 | $8,346,000 | +53.8% | 99,642 | -34.2% | 0.04% | +76.2% |
| Q3 2020 | $5,427,000 | +2280.3% | 151,456 | +1344.1% | 0.02% | +2000.0% |
| Q3 2018 | $228,000 | – | 10,488 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |